Brigham Young University and professor Daniel Simmons sued Pfizer in 2006, saying Simmons had made a critical discovery that led to the development of Celebrex but that he and BYU had been denied a share of profits. Pfizer agreed to settle the case earlier this year for $450 million. That lawsuit was not associated with a pending securities fraud case against Pfizer.
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account. See more about comments here.